Clinical trials: Breast Cancer Stage IIIA
Breast Cancer, Fatigue
Studying Biological Markers of Fatigue in Women With Residual Invasive Breast Cancer Enrolled on Clinical Trial NSABP-B-45
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to fatigue.
- Trial name
- NCT00914043
- Testing
- gene expression analysis, microarray analysis, polymerase chain reaction
- Sponsor
- NSABP Foundation Inc
Breast Cancer, Metastatic Cancer
Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Zoledronate may delay or prevent the formation of bone metastases. It is not yet known whether chemotherapy and/or hormone therapy are more effective with or without zoledronate in preventing cancer recurrence and bone…
- Trial name
- NCT00072020
- Testing
- zoledronic acid, adjuvant therapy, neoadjuvant therapy
- Sponsor
- University of Sheffield
Breast Cancer
Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- EPHOS-B (NCT01104571)
- Testing
- trastuzumab, lapatinib ditosylate, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 257 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
Diet and Exercise or Normal Care in Overweight or Obese Women Who Have Undergone Treatment for Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Studying diet and exercise interventions in overweight and obese patients with breast cancer may help doctors learn more about how to help patients lose weight and change their body composition.
- Trial name
- NCT00689975
- Testing
- behavioral dietary intervention, exercise intervention, counseling intervention
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Sheffield Hallam University
Breast Cancer, Male Breast Cancer
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
Tipifarnib may stop the growth of breast cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00470301
- Testing
- tipifarnib, paclitaxel, doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Breast Cancer, Stage II Breast Cancer
Exercise Program for Early Breast Cancer Survivors
Rationale: Exercise therapy may improve the quality of life of breast cancer survivors. Purpose: This randomized clinical trial studies exercise therapy and quality of life in postmenopausal early breast cancer survivors…
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT01140282
- Testing
- questionnaire administration, quality-of-life assessment, management of therapy complications
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Southern California
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Effect of Advertisements on Treatment Compliance in Women With Breast Cancer
RATIONALE: Measuring how advertising affects treatment compliance in women with breast cancer may help doctors plan the best treatment.
- Trial name
- NCT00462410
- Testing
- counseling intervention, psychosocial assessment and care
- Volunteers
- 65 people
- Sponsor
- Institut Bergonié
Breast Cancer
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
RATIONALE: Drugs used in chemotherapy such as epirubicin and docetaxel use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00066443
- Testing
- pegfilgrastim, docetaxel, epirubicin hydrochloride
- Where
- 5 sites in Canada
- Volunteers
- 93 people
- Sponsor
- NCIC Clinical Trials Group
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Neo-Adjuvant Chemotherapy (TAC) With or Without Zoledronic Acid in Treating HER2-negative Breast Cancer Patients
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, docetaxel, and zoledronic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NEO-ZOTAC (NCT01099436)
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- Netherlands
- Volunteers
- 250 people
- Sponsor
- Borstkanker Onderzoek Groep
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00895414
- Testing
- doxorubicin hydrochloride, enalapril maleate
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Breast Cancer
Multifunctional Magnetic Resonance Imaging in Predicting Breast Lesions in Women Undergoing Mastectomy for Breast Cancer
RATIONALE: Diagnostic procedures, such as multifunctional magnetic resonance imaging, may help doctors learn the extent of disease and plan the best treatment.
- Trial name
- NCT00602316
- Testing
- gadolinium-chelate, conventional surgery, magnetic resonance imaging
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Breast Cancer
Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00949598
- Testing
- letrozole, tamoxifen citrate
- Where
- France
- Volunteers
- 177 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
This randomized phase II trial studies how well electroacupuncture therapy works in reducing chronic pain in patients following surgery for stage I-III breast cancer.
- Conditions
- Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
- Trial name
- NCT02754752
- Testing
- Electroacupuncture Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- M.D. Anderson Cancer Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
This clinical trial studies the effect of a culturally based brief expressive writing intervention in improving the health of Chinese immigrant stage 0-III breast cancer survivors.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04754412
- Testing
- Behavioral, Psychological or Informational Intervention, Best Practice, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00616967
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, vorinostat
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
RATIONALE: A walking program may improve the ability to carry out daily activities after donor bone marrow transplant. PURPOSE: This randomized clinical trial is studying a structured walking program to see how well it works…
- Trial name
- NCT00445731
- Testing
- exercise intervention, management of therapy complications, observation
- Volunteers
- 115 people
- Sponsor
- University of Minnesota